Member Info for dactions

Sorry mbev you missed out on some small action today - it's hardly back to anything really where it should be, but as you correctly surmise that for us Long Term Holders we're just pleased to see some blue for a change and to quote your words "stare at a slightly smaller loss". You have been very measured in your comments but I do echo your words too: "it just highlights how bad the Board of Directors really are." Good Luck mbev with your investments.

The immediate response in the SP following the Woodford report today is good but irrespective as to wheher there is maintained upward SP momentum, the report's author is reassuring for all us long-term holders as it confirms very clearly in a judicious use of words, all the mixed sentiments we have all expressed on this BB for very many months. I feel very reassured.

Cadburyhill states the pertinent sentences. Full report is here: https://woodfordfunds.com/words/insights/wpct-interim-results-2017/?utm_source=insight-alert&utm_medium=email&utm_campaign=wpct-interim-results

It means I think that Spreadex is the new owner of a large holding of OBT shares. Could it be from the original leading light of OBT, Frank Scolaro, who has stepped down as a Director and who has a very substantial shareholding ? I saw on (share p rophets) website comments re. a hefty Spreadex buy in respect of another Company: “Yet to see Spreadex make a loss when they buy in... they usually bag several times over. they will have done their due diligence and are happy buying xxx million shares! All lining up here” So, it matches my feelings re. OBT in that its shareprice is underpinned by the Company finance deals this past year of 19-20p and the recent strong Q2 statement plus broker reviews anticpating shareprice targets of 36p and above. In my opinion of course so do your own research.

Thank you Freddie. It's a bit like learning a foreign language - reading through, one's brain switches off after a while. However, that said though, this article does make one realise just why the rewards will be incredibly high for Reneuron and its shareholdrs when it reaches a commercial conclusion from the PISCES trials (Ischemic stroke). We know that patients on the PISCES II trial, despite long after their initial stroke when medical experience says they'll be NO further improvement, actually registered meaningful improvement. But, for Reneuron to prove that it is because of their CTX treatment is the conundrum which remains to be solved. For anyone new to Reneuron, here is a paragraph I extracted from the report> QUOTE Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study.[Lancet. 2016 Due to the small number of patients treated in the trial, their heterogeneity as a study population, and the open-label, single-arm study design, it is not possible to draw reliable conclusions about the effects of CTX cell implantation on neurological or functional recovery. However, it was possible to note that despite the selection of chronic, stable patients at late stages after stroke, most showed some improvement across several indices of function [9]. Whether attributable to cell implantation or to other factors, such as extra medical attention, a change in this patient group suggests that trials of interventions are worthwhile late after stroke, when recovery is not generally believed to be attainable. The researchers also described anecdotal accounts of reduced spasticity, minor return of finger movement at phalangeal joints, and improved visual perception and better bed-to-chair transfers, which were supported by the changes in health-related quality of life, activities of daily living, and neurological impairment. ENDQUOTE

bberman1 - yes it is quiet - even before when we were coming up from 8p - it was quiet but a steady as you go movement upwards with the shareprice. Now, we're consolidating which was bound to happen - there's been a lot action this past 12 months, notably the WoodBois acquisition but the recent RNS was exceedingly positive - barring natural disasters, the next results should be good. I saw that OBT is a favourite of TW and is one of his current Hotstockrockets. Two days ago he updated his previous recommendation (it's always good when someone else agrees your own opinion) - see below: QUOTE Obtala – some recent share price weakness, but not operational weakness: Since we previously updated on Obtala (LSE:OBT) at the start of this month, there have been developments including a quarterly report. The shares are down, but is this fair ? The latest from the company emphasises a “transformational quarter” headlined by the completion of the WoodBois acquisition, more than doubling potential production capacity of tropical hardwood timber and providing a global timber trading platform run by principals with decades of trading experience. It is though noted “historic trading revenues (c.$15m) limited by availability of trade finance which Obtala is seeking to address” – and indeed it has already increased WoodBois' credit facility by 36% and is to work on “substantially increasing” this. Additionally, the acquisition of WoodBois is expected to “have considerable operating and revenue synergies for our forestry business in Mozambique” – itself achieving several key milestones in the quarter. Here, six management plans the company reported to be working on in the Q1 update are now approved and it is currently operating in 2 concessions, with an additional 4 expected to be operational “shortly” and installed new equipment already beginning to show in increased production. There has also been recent progress in Tanzania. With also potential future upside with the company “continuing to investigate whether a dual-listing may be appropriate to increase liquidity and give Asian investors an easier platform with which to invest”, we continue to consider a share price down from above 22p last month to currently circa 17p an incorrect appraisal. With this though comparing to a circa 9p share price a year ago, we understand there is a relatively small share overhang of c 1-2 million shares. However, expecting that issue to clear in relatively short order as the underlying value here is made further clearer, with a target of 30p+, our stance at current levels is still BUY at up to 21p. ENDQUOTE

Opti as many know is one of TW's Hotstockrockets shares. It's not yet really taken off but certainly has the promise to do so IMO. Like all shares on AIM, things can be fast moving one way or the other but it seems hard to judge at the moment. Here's TW's latest update published yesterday. QUOTE Optibiotix (OPTI) has announced that its German partner HLH has achieved product registration of capsules containing the Optibiotix product LPDL and started commercial sales to drug stores on July 24. HLD will also market the capsuled under the brand name Lactobact® LDL-Control direct to consumers on its online platform. So how important is this? We quote: "Sales revenues are difficult to estimate in this new and developing market but are likely to be in the low to mid six figure in the near term growing as HLH builds market presence.six figure is £100,000 or multiples thereof. What Optibiotix is saying is that on an incredibly high gross margin it should be booking ales of anywhere up to £600,000. This is for one product in one country. And on a deal signed just last month. The sales pipeline is pregnant with a raft of other deals as Optibiotix has multiple products and there are a lot of markets other than Germany." Steve O Hara stated with this release: " We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL® as the active component in a wide range of pharmaceutical and consumer products around the world." And then there are all the other products. This is the ARM business model. On the sort of margins Optibiotix will make as the owner of IP it will not take that many deals like the HLH one for gross profits to easily exceed what are relatively low fixed costs. And thereafter it all drops to the bottom line and fast. That is why this remains such an exciting stock and we are getting close to inflexion point. There will be a raft of announcements over the coming months of other deals like HLH and indeed we expect one deal to be so large it dwarfs HLH. As the market wakes up the shares will zoom ahead. They are now 65p-68p and are a BUY at up to 80p with a target to sell of well over 100p well before Christmas. ENDQUOTE

With the RNS just released at 11am, it is good to see that the BOD has between them purchased approx £160,000 worth of shares - it's never a bad thing when the Directors spend their own money !

Perhaps my sarcasm was misplaced. Just seen a 2,380,000 purchase at 1.7p just go through. Would like to think this was the start of a turn in fortunes ?

I sympathise Karny - I dread to think what I paid for Zoo originally and adding yet more on so-called averaging down. Green has a lot to prove as shareholders have borne all the pain through these many years. The sp dilution that has happened after one placing after another, one major Institutional holder after another. The only winner has been Green - 'winner' even for him is hardly the right word - but his has been a paid job all this time whilst for the early/original shareholders it has effectively been an almost complete financial loss. Significant improvement in ZOO's results needs to be seen quickly - otherwise the market will not believe that 'this time' unlike all the other times, their prospects are really bright !

Umm - the buys and sales on LSE seem to reflect reality as I was asked for 1.684p for a dummy purchase just now. Perhaps the joint broker hasn't worked out a strategy yet ?!?

I would expect some benefit to the sp going forward. Although there's nothing better than solid news on their research projects, nevertheless fresh blood (excuse the pun) will always yield some results.

Good point Freddie - but this is what RENE should be telling us. Can we get the question to Michael Hunt for him to answer ?

It's quite phenomenal what has been achieved in one quarter - management enthusiasm is very evident through the lengthy RNS. As Chairman Miles Pelham says - it's been a transformational quarter. The immediate outlook for the shares is excellent IMO. Quote: Q2 2017 was a transformational quarter for Obtala. On 30 June 2017, we announced the completion of the $14.6m acquisition through Argento of WoodBois International ApS ('WoodBois'), a deal that more than doubles our potential production capacity of tropical hardwood timber and provides us with a leading global timber trading platform run by principals with decades of trading experience. WoodBois, like our forestry business in Mozambique, is still undergoing a rapid scaling of production. Having commenced this process in Spring 2016, WoodBois' infrastructure and operations team have already been in place for a full year and production and revenue numbers for H1 2017 are extremely encouraging with the outlook for H2 2017 enhanced following the arrival of two new bulldozers in July that will increase production in the forest. WoodBois' timber trading business also showed a strong start to the year despite more capital being allocated to the Gabon forestry operation in the months leading up to our acquisition. We have already increased WoodBois' credit facility by 36% and intend to seek additional trade finance to support higher trading volumes. EndQuote

Just 3 deals so far today - all of which are presumably Buys - little more than 150,000 traded and the bid strengthens by .25p. Just goes to show how easily this share could quickly move forward with a little buying momentum.

last night in Mayfair anyone ?

Umm, I'm not sure what the RNS would say Balerno. But picking up on an earlier post, I listened to a leading opthalmic consultant referring to journals promoting the trials in Retinitis Pigmentosa. She felt that the science is looking good but recognises it is a slow process. I suppose Micahel Hunt could announce they have now filed their application to the FDA seeking approval to switch from the fresh hRPC formulation to the new cryopreserved formulation for dosing of the third and final Phase I dose cohort of their ongoing US Phase I/II clinical trial in retinitis pigmentosa (RP) patients. I feel sure Freddie this share will come good. Good luck to you.

some of these trades today - can't quite see why they bother. Some patience required here - they'll come good.

here today from short-term punters.

It will help support - albeit in a small way. Edison's reports have been consistent in their tone which aids credibility. This time last year with the shareprice at 3.14p, they upped their forecast from 7.4p to 7.9p. Then followed up in August 2016 (sp 3p) with again a forecast of 7.9p and in December (sp 2.88p) they argued why their valuation could be increased to 9p a share given that we had RENE then had posted Positive Phase II Stroke data. We know this is a slow burner but it helps aid sentiment in the meantime.